NasdaqGM:SESN

Stock Analysis Report

Executive Summary

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.

Risks

  • Sesen Bio has significant price volatility in the past 3 months.

Share Price & News

How has Sesen Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.1%

NasdaqGM:SESN

0.5%

US Biotechs

-0.7%

US Market


1 Year Return

-34.9%

NasdaqGM:SESN

-8.0%

US Biotechs

-0.5%

US Market

SESN underperformed the Biotechs industry which returned -8.1% over the past year.

SESN underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

SESNIndustryMarket
7 Day-5.1%0.5%-0.7%
30 Day-11.1%1.0%-3.0%
90 Day-43.1%3.2%0.9%
1 Year-34.9%-34.9%-7.3%-8.0%1.7%-0.5%
3 Year-78.0%-78.0%9.3%5.6%39.5%30.4%
5 Year-90.4%-90.4%7.7%2.7%54.1%37.0%

Price Volatility Vs. Market

How volatile is Sesen Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sesen Bio undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Sesen Bio's share price is below the future cash flow value, and at a moderate discount (> 20%).

Sesen Bio's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Sesen Bio is loss making, we can't compare its value to the US Biotechs industry average.

Sesen Bio is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Sesen Bio, we can't assess if its growth is good value.


Price Based on Value of Assets

Sesen Bio is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Sesen Bio expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

32.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Sesen Bio's revenue is expected to grow significantly at over 20% yearly.

Sesen Bio's earnings are expected to grow significantly at over 20% yearly.

Sesen Bio's revenue growth is expected to exceed the United States of America market average.

Sesen Bio's earnings growth is expected to exceed the United States of America market average.

Sesen Bio's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Sesen Bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Sesen Bio performed over the past 5 years?

-7.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Sesen Bio does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Sesen Bio's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Sesen Bio's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Sesen Bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Sesen Bio has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Sesen Bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Sesen Bio's financial position?


Financial Position Analysis

Sesen Bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Sesen Bio's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Sesen Bio has no debt.

Sesen Bio has no debt compared to 5 years ago when it was 9.6%.


Balance Sheet

Low level of unsold assets.

Sesen Bio has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Sesen Bio has sufficient cash runway for 2.2 years based on current free cash flow.

Sesen Bio has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 45.1% each year.


Next Steps

Dividend

What is Sesen Bio's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Sesen Bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Sesen Bio's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Sesen Bio has not reported any payouts.

Unable to verify if Sesen Bio's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Sesen Bio has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Sesen Bio's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Thomas Cannell (57yo)

1.0yrs

Tenure

US$2,009,874

Compensation

Dr. Thomas R. Cannell, DVM, is President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June 8, 201 ...


CEO Compensation Analysis

Thomas's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Thomas to compare compensation growth.


Management Age and Tenure

1.0yrs

Average Tenure

57yo

Average Age

The average tenure for the Sesen Bio management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.6yrs

Average Tenure

60.5yo

Average Age

The tenure for the Sesen Bio board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Greg Verdine (60yo)

    Co-Founder

    • Tenure: 0.0yrs
  • Greg Adams (60yo)

    Chief Scientific Officer

    • Tenure: 0.0yrs
  • Glen MacDonald (68yo)

    Chief Technology Officer

    • Tenure: 0.0yrs
  • Mark Sullivan (48yo)

    General Counsel & Corporate Secretary

    • Tenure: 0.0yrs
  • Chris Garcia

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Rich Fitzgerald (55yo)

    CFO, Secretary & Treasurer

    • Tenure: 1.8yrs
    • Compensation: US$664.52k
  • Casey Weaver

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Thomas Cannell (57yo)

    President

    • Tenure: 1.0yrs
    • Compensation: US$2.01m
  • Dennis Kim (50yo)

    Chief Medical Officer

    • Tenure: 0.7yrs
    • Compensation: US$709.28k
  • Erin Clark

    Vice President of Corporate Strategy & Investor Relations

    • Tenure: 0.0yrs

Board Members

  • Dan Lynch (61yo)

    Director

    • Tenure: 5.5yrs
    • Compensation: US$130.30k
  • Wendy Dixon (64yo)

    Chairman

    • Tenure: 2.7yrs
    • Compensation: US$257.57k
  • Patricia D'Amore (67yo)

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Jane Pritchett Henderson (53yo)

    Director

    • Tenure: 5.5yrs
    • Compensation: US$133.43k
  • Peter Campochiaro

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Jay Duker (60yo)

    Director

    • Tenure: 4.6yrs
    • Compensation: US$113.78k
  • Chris Garcia

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Reza Dana

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Casey Weaver

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Thomas Cannell (57yo)

    President

    • Tenure: 1.0yrs
    • Compensation: US$2.01m

Company Information

Sesen Bio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sesen Bio, Inc.
  • Ticker: SESN
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$113.418m
  • Shares outstanding: 101.27m
  • Website: https://www.sesenbio.com

Number of Employees


Location

  • Sesen Bio, Inc.
  • 245 First Street
  • Suite 1800
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SESNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2014
PCBKDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company’s le ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 00:31
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.